Health
PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19 – Small Caps
Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma….
Six dogs have completed PharmAusts (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma.
During the March quarter, PharmAust revealed six dogs with stage four to five B-cell lymphoma had completed evaluation across five trial sites.
However, one dog was not in compliance with the trial process and was subsequently withdrawn.
PharmAust noted the remaining dogs side-effects were less than conventional anti-cancer drugs, with only…
-
Noosa News11 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News19 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News16 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Business18 hours ago5 things to watch on the ASX 200 on Wednesday 21 May 2025